• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    METHOD FOR PRODUCING CEFALOSPORIN-1-OKSVDA DERIVATIVES of the general formula t g HfN -A; -fe-HH v; “Evoacsonic 4, where R and R are methyl or R and R together are 3-propylene; R - 1H-1,2,4-triazole-3-yl, 5-amio-1H-1,2,4-triazol-3-ip, 2-amino-1,3,4-thiadi .azole-5- Ш1, 2-Ч ercapto1, 3,4-thiadiazol-5-Ш1: shga 3-hydroxypyrndyl-2, in the form of syn-isomers, it is also possible that the t-butyl 7-amino-3-bromomethyl-Zecem-4-carboxylic acid-1-oxide tert-butyl ester is acylated with the acid of the general formula .S. HE CH R. n. O-cJ-doo-d-cJH, Rt CH3 where R. and Rj have the indicated meanings; R. group protecting the amino group, such as trityl, as a syn-ismer, in an inert organic solvent of a solvent such as methylene chloride, in the presence of carbodiimide and an organic base at room temperature, the resulting product is reacted with a heterocyclic thiol of the formula RjSH where Rj has the indicated values, CO in an environment of an inert organic 00 00 solvent, such as dimethylformamide, in the presence of an inorganic or organic base at room temperature, followed by removal of g protecting amino and carboxy groups by acid hydrolysis and allocation of the target product.
    公开号:SU1114338A3
    申请号:SU823519544
    申请日:1982-11-30
    公开日:1984-09-15
    发明作者:Лабев Бернар；Сали Али
    申请人:Санофи (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to a method for producing new cephalosporin antibiotics, namely, cephalosporin-1-oxide derivatives, which can be used as medicines in medicine. A known method for producing biologically active 3,7-disubstituted cephalosporins, in particular (2-aminothiazolyl-4) -2-alkoxyiminoacetamido-3- (1-substituted tetrazolyl-5) thiomethyl-3-cephem-4-carboxylic acids, is that 7-amino-3-gapoidmethyl-3-cephem 4-carboxylic acid is acylated with 2- (2-protected aminothiazolyl4) -2-alkoxyiminoacetic acid in inert organic solvent in the presence of a carbodiimide and an organic or inorganic base upon cooling or with temperature, the resulting product is reacted with corresponding T-d-iNh t ° t where R and R are methyl or R and R2 together are 1,3-propylene; RJ-1H-1,2,4-triaol-3-yl; i 5-amino-1H-1,2,4-tri azol-3-yl, 2-amino. 1,3,4-thiadiazol-5-Sh1, 2-mercapto-1,3,4-thiadiazol-5-yl or 3-hydroxypyridyl-2 as san isomers by acylation of 7-amino-Zbrommethyl-3 tert-butyl ether -cepheme-4-carboxylic acid I-oxide with an acid of general formula II Ksch} UNH, (J-COOH 1 Hb N RI o- -doo ct-cJH, Ff CJH, in the form of a san isomer, where RI and R have the indicated R-group, scintillation of the amine group, such as trityl, as a sun-isomer, with a 1-substituted tetrazolyl-5-thiol in an inert organic solvent medium in the presence of an organic or inorganic base at room temperature or The aim of the invention is to obtain new antibiotics of the cephalosporin series, expanding, an arsenal of means for affecting a living organism, with lower values of the minimum inhibitory concentration. This goal is achieved mainly on cephalosporins known in the range ; acylation reactions of the 7-amino group and the exchange of halogen for the heterocyclic thio group in the 3-methyl substituent by the method of obtaining derivatives of cephalosporin-t-oxide of the formula I t-J J-NY "2-S-K3 JooH I - in a medium of inertial op an anionic solvent, such as methylene chloride, in the presence of carbodimide and an organic base at room temperature, by reacting the resulting product with a heterocyclic thiol of formula III where R has the indicated values, in an inert organic solvent, such as dimethylformamide, in the presence of an inorganic or organic base at room temperature temperature with the next. removal of groups, which are amino and carboxyl acid groups, by hydrolysis and targeting of the desired product. The products of the cephalosporin series do not have a clear melting point, and with the help of temperature only, their decomposition points cannot be used in pxapjKTjev, therefore they are harvesterized using their nuclear magnetic resonance spectrum recorded in the 60 MHz range, and hexamethyldisnloxane is used as an internal standard.
    3
    in the examples, the following abbreviations are used: C singlet; D - doublet; T - triplet: K - quadruplet; DC - doublet doublet; Sh.S. - wide singlet; M - mule tiplet; AB - AB system; J - represents a permanent link.
    In addition, KpQMe conducted elementary microanalysis in each case; the obtained data were in full accordance with the specified formulas.
    Example 1. (2-Amino-Atiazolsh1) -2- (2-rboxy-2-propyloxyimino) -acetamido-3-1 l H 1,2,4triazol-3-ylthiomethyl1-3-cephem-18-oxide-4- carboxylic acid, synisomer (CM 40 765)
    N-NH
    Rj CHj;
    H
    N
    a), (2-Tritch1amino-4-thiazol1sh) -2 - (. butoxycarbonsh1-2propyloxyimino) -accetamidoJ-3-brommegyl-3-cephem-4-carboxylate tert.butyl f-S-oxide, syn-isomer.
    (V) R,
    A STB solution of 5 g of 7-amino-3-bromomethyl-3-cephem-4-carboxyl-tert-butyl tS-hydrochloride hydrochloride in 90 ml of methylene chloride was added 1.72 ml of triethylamine, 7.57 g of 2- 2-tritylamino-4- tiazolin -2-t-butoxycarbonyl-2-propyloxyimino acetic acid, 2.84 g of dicyclohexylcarbodatmide and 0.1 g of hydroxybenzotriazole. The mixture was stirred for 15 hours at ambient temperature, then the resulting dicyclohexyl compound was separated by filtration.
    -. „- -. . , - 4-V After evaporation of the solvent
    the residue is chromatographed using a silica gel column (50 g). Using as a eluate a mixture of hexane-ethyl acetate (50-50, v / v) is obtained. 4.3 grams of IS “product”.
    J, .- NMR spectrum (in solution with dtmethyl dymethylsulfoxy-1J treatment-secret. De7: 1H with 8.70.RRN SS-Trit, C - 1H with 8.07 ppc (NH-CO, D, 3 9 Hz) .15N with 7, 25 pps (H trit C) - 1H with 6.72 (H thiazole, C) - 1H with 5.88 pps ((Well, DD,:, 9 Hz; 1 g 4 Hz) - 1R with 4.96 ppm (Hg, D, 1 4 Hz) - 2H with 4.50 ppm (, AV, dv - 12Hz) 2Y from 3.77 ppb (CH2 in 2, W.S.) - 9H
    143384
    with 1.45 ppm (CHj, C) - 6H with 1.37 ppm-s-c
    one
    CHj (-9H from 1.27 ppm
    CH,
    one
    .0.
    -C-CH, I CH.
    B). (2-Tritch1-amino-4-thiazo-0 | Lyl) -2- (2-tertiary butoxycarbonyl-2-propyloxyimino) -acetamido-3-1H1, 2,4-triazol-3-ylthiomethyl-3-cefemcarboxylate-4-tertiary. -butyl-1-S-oxide, syn-isomer NH
    CH
    R, R
    2
    3
    In a solution of 2.8 g of the bromine-containing derivative obtained in Example IQ.B 20 ml of N, H-dimethylacetamide
    0 add 0.308 g of 3-mercapto 1H
    1,2,4-triazole, then 0.4 ml of triethyl amine. After 3 hours, during which stirring was carried out at ambient temperature, the solvent was evaporated under vacuum, and the residue was dissolved in 80 ml of methylene chloride. The treatment is further carried out using chromatography on a column containing 120 g of silica gel. When elution with etchtase receive 2.3 g of the desired product. with). CM 40.765.
    Stir for 30 minutes at an ambient temperature of 1.06 g of the product obtained in Example 1b
    in 10 ml of trifluoroacetic acid. The mixture is evaporated under vacuum to a volume of 5-6 ml, then precipitated by adding 200 ml of anhydrous ether. The precipitate is collected, washed with ether anhydride and dried. Repeat the previous “I” operation one more time and similarly, 0.6 g of the desired product is obtained.
    NMR spectrum: 5H with 9-10.5 ppm (NH triazole, NH, 2 COOH, bhp) - 2H with 8.40 ppm (NHCO, H triazole.M) - 1H with 6.87 ppb (AND triazole, С) - 1Н с5.97 ррп (Нg. М) - 1Н с 4.92 ррт (Н, Д, - 4 HZ) - tН с 4.5 ppm (CHjS-, A of the system АВ, 1дц 13 Hz) - 1Н с 4.30 ррт (CHjS, В systems АВ, J - 13 Hz) 2Н с 3.80 ррш (CH ,, ш.с.) - 6Н с
    / CH,
    WITH),
    (-WITH

    CH
    PR and M e p 2. (2-Lmino-4tnaeolyl) -2- (2-carboxy-2-propyloxy and o) -acetam1zo | -Z-2 amino1, 3,4-t adiaeol-5-yl and) methyl1 -3-cephem-1-8-ox-d-4-carboxylic acid, syn-isomer (CM) (I) R, - Rj-CH.jjRj -la). 7- | jZ- (2-TpirTKiiaMHHo-4-gnazol. Butrxycarboyuoxyim acetamido3 -3-C2-amino-, 3,4 thiadiazol-5 lymphotype -3-cephem-4- sarbox lattretichny. -Butyl-1-8-ox1a; - isomer of NN Rj "Ke-tiH3i for 16 hours at ambient temperature the mixture is stirred t g of brominated derivative according to iipitMera 1 a) 0.18 g 2-amino-4-merteto1, 3,4-thiadiazole 0.12 g bicarbonate potassium in 10 ml of d meth lformam yes. The solvent is evaporated off under vacuum. The residue is dissolved in methylene chloride. The solution is washed with water, followed by a saturated aqueous solution of sodium chloride. Dry over magnesium sulfate, then concentrate the solution to a volume of 5 ml. Next, the treatment is carried out on a chromatographic column with silica gel (25 g). With the help of blending with a mixture of ethyl acetate.
    Xid-
     one
    x N,
    p- | C-UNAF
    No
     GMFR product R
    ji, .- ..
    3 40.804N-N
    -t. D n
    R
    About NYUYAMR-spectrum
    TTz) 1H with 8.40 ppm (NIO), D, J 4H with 8.5-tO ppm (N «2, 2 COOH) - 1H with 6.83 pu (H thiazol. C) - 1H with 5.96 ppm (H, DNY, i 9 Hz, Jg 4 Hz) - 1H with 4.93 ppb (Hg, D, 1 - - 4 Hz) - 1H with 4.60 ppm (CHjS, A of the system AB, Zdv 13 G) - 1H with 4.05 ppm (CHjS, V systems AV, Tdv "13 Hz) - 2H from 3.81 ppm (CHjS- O
    , CHj
    broadband (- 6H with 1.42 ppm) - C; WITH).
    SNS Tat / Hexane 90-10 (o / o) get 1 g of the desired product. B) CM 40.803. Within 45 minutes at 20 ° C, a mixture of 0.55 g of the product obtained according to Example 12c and 6 UI of fluoroacetic acid is poured. The mixture is concentrated under vacuum to a volume of 3 ml (then precipitated by adding simple. The solid is separated dried over phosphorus anhydride. 0.39 g of the desired product is obtained. NMR spectrum: 1H with 8.5 ppm) (NO, D j 9 Hz) - 6H with 6.5-8.5 ppm (2NH, 2 COOH, M) - W with 6.90 ppm (N-thiazole, C) - 1H with 5.97 ppm (Well, M) 1H with 4.96 ppm (H, fl,) - 1H with 4.45 ppm (CHjS. A system AB, 1d0 P Hz) - 1H with 3.90 ryut (CHgS, B systems AB, Zdv "13 Hz) - 2H with 3.85 ppm (CH., Bhp) - 6H s, CI5. 1.45 ppm (-C C) Examples 3l-5. Operate as in Example 2a), starting from bromine-containing prod from npimepa}) vary the type of thiol used. The removal of the arraged groups of the products obtained is carried out, as indicated in Example 2p), various compounds of the formula (X) are obtained, summarized in Table 2. 1. Table1

    When I Shfr product
    440.
    Ajjxj-nha
    BUT
    540.953
    P
    XiiJ
    H with 8.43 ppm (NHCO, D, I 9 Hz).
    Continued table. I
    NMR Spectrum
    7H with 8-10 ppm (NH thiazole, 2 COOH, bhp) - 1H with 8.45 ppm (WSSD, J 9 Hz) - 1H with 6.85 ppm (H tyasol. C) - 1H with 5 , 97 rrga (H |. DP, J, Hz, 1g Hz) - 1H with 4.95 ppm (N, D, 7 4 Hz) - 1H with 4.30 ppm (CH2S, A of the AB system, 1d9 3 Hz) V / Lirf V “rav- oll-ll y -. - 1H with 3.90 pprgo (SNLZ. In the system AB,
    1H with 3.90 ppm (SNLZ, V systems, 3fte 13 Hz) - 2H with 3.85 ppm
    / sns.
    s.s.) - 6N with 1.45 ppm (-C С
    S
    sn,
    5H with 9.0 ppm (2 COOH, NH2, OH M) 1H with 7.87 ppm (P (, pyridine, M) - 3N with 6.95 ppm (H4 and Hj pyridine, H thiazole, M) - 1H with 5.95 ppm (H, DC, J, 9 Hz, J2 - 5 Hz) - 1H with 4.95 ppm (Hg, D, J 5 Hz) - 1H with 4.60 ppm (CH2S, A of the system AB, 13 Hz) OTH with 3, 80 ppm (CHjS- O and CHjS, B
    11 f J J v iirtu f xy eyi-j
    -.- AT - “4 L,
    AB, M) systems - 6H with 1.45 ppm
    (-S.).

    Ch.
    P p and M e, p 6. (2-Amino-4 | Giazolium) -2- (carboxy-1-cyclobutyloxyl) acetamidoL-3-3-oxy-2-nftPHDinylthiomethyl3 -3-cephem-1-5-oxide -4 carboxylic acid, syn-isomer (SM4G646).
    BUT
    RnVCcHi).) -R ..
    ei) (2-Trithylamino-4-thiazolvl) -2- (t-tre, i.-butyl-oxfaxarboat t-cyclobutyloxyimino) acetamido | 3-bromomethyl 3-cephemcarboxyl-4-tertiary, -3-oxvda, syn-eeo. measure RI + R (GHg) 3.
    is a solution of 4.4 g of chlorine hydrate 7azhdo-3-bromomethyl-3-cephem-4-car-. bozhsilat-tertiary-butyl-1-S-oxide in 70 ml of anhydrous methylene chloride, in a nitrogen atmosphere, 1.5 ml are added: triethylamine, 5.1 g of 2- (t1 shamin-4-thiazolyl) -2- (1-tertiary). 6toxycarbon l-1-hdaclobutylocrimino) acetic acid, syn-isomer 2.4 g of dicyclohexylcarbodiimide and
    0,, 1 g of 1-hydroxybenzotriazole. The pep mixture is stirred for 1 h at an impeller temperature, then the resulting dicyclohexed compound is filtered by filtration, and the solution is concentrated to a volume of 20 ml under vacuum.
    Next, the solution is treated on a chromatographic column of silica gel (150 g). By using a mixture of hexane-ethyl acetate 40-60. (Vol / rb-g), it is obtained after. 5 {solvent evaporation 4.8 g is. coma product.
    NMR spectrum: 1H with 7.90 ppm (NHCO, A, J - 9 Hz) - 15H with 7.26 ppm (aromatic H, C) - 1H with 6.97 ppm (NH-trityl, bp) - 1H with 6.65 ppm (H thiazole, C) - | H with 6.18 ppm (H, DC, Jt «9 Hz, 1 g 4.5 Hz) - 2H s. 3.4 ppm (, bhp) - 6H with 1.52, 6 ppm (cyclobutnl, M) - 9H with
    jHs
    1.46 ppb |
    doQH-dH3,
    Lnz (Nz, s /. 1,36 ppm in). (2-Tritylamino-4-thiazolyl) -2- (1-tertiary-butoxycarbonyl1-cyclobutyl-oxyimino) -acetamido 3-3-hydroxy72-pyridinylthiomethis1-D-3ephem-4-carboxylate-tert-butyl-1-Soxide; isomer To a solution of 0.164 g of 3-hydroxy 2-mercaptopyridine in 6 ml of dimethyl forms, 0.12 g of g of bicarbonate was added, and then 1 g of bromine-containing product obtained in Example b. The mixture was stirred for 16 h at ambient temperature, then poured into 50 ml of ice water. The precipitate is entrained and washed with water. The solid is dissolved in methylene chloride, the solution is dried over magnesium sulphate and concentrated to a volume of 5 ml. The treatment is then carried out on a chromatographic column with 20 g of silica gel. By elution with a mixture of hexane-ethyl acetate 40-60 (volume / volume), 0.85 g of the desired product is obtained. C) CM 41646. A solution of 0.8 g of the product obtained in Example 68) in 8 ml of trifluoroacetic acid is kept for 45 minutes at ambient temperature. The solution is evaporated to dryness in vacuo and the residue) washed with ether. The solid is recovered and dried under vacuum in the presence of phosphoric anhydride in order to "obtain 0.5 g of the desired product. NMR spectrum: 1H with 10.40 ppm (OH, i.e.) - 1H with 8.70 ppm (NHCO, D 3-8 Hz), VH with 7.80 ppm (H pyridine, D, J 5 Hz ) - 2H with 7.1.0 ppm (NHj, br) with 2H from 6.95 (H4 and H, pyridine, M) - 1H from 6.80 rrga (H thiazole. C) - 1H from 5.90 ppm (, DC, J, 3810 "8 rn, h 5 Hz) - 1H with A, 95 ppc (N., DL 5 Hz) - 1H with 4, b5.rt (CH., S, D ,: U Hz) - OZ with 3.80 ppm (CHjS- O and, M) AN with 2.40 ppm (C% COOH, M) CH 2H with 1.90 ppm (Gr „). The products of formula (I) are examined in order to study their pharmacological properties, and more precisely their bacteriostatic action. The bacteriostatic effect in vitro was determined in solid medium by the dilution method. The results obtained are expressed in minimum inhibitory concentrations (IPC mg / ml) and relate to different types of enterobacteria and Pseudomonas. As a comparison, the results obtained for two close products 2, namely (2-amino-4-thiazolyl) -2-carboxymethoxyiminoacetamido3 -3-2-pyridylthiomethyl-D-3-cephem-1-5-oxide-4carboxylic acid, b1sh isomer HT-i-io-wHn, l; m1 oTv-b..eU; odHiCooH eotw (Compound A) and (2-amino-4-thiazolyl) -2-toxiimiminoacetamido3-3-triazole1, 2,4,3-ylthiomethyl3 -3-cephem-tS-oKsid-4-carboxylic acid, syn-isomer i V H- je-HH-T-gk Ch-i ,. UN (compound B) In table. Figure 2 shows the minimum component concentrations of the test compounds (mg / ml). These results show the activity of cephalosporin products to the species of bacteria that are generally not very sensitive to antibiotics of the cephalosporins family, namely Enterobacteries and Peeu oroonas. Table 2
    Unlike products A and B, the products of the formula {I) show activity towards the species of Pseudomonas, good activity against Enterovacter, and also have equal activity with compounds A and I to Proteus, Serratia, .Escheriehiacoli.
    i At the same time, animal tests showed no signs of toxicity of the test products.
    Thus, these products can be used as anti biotics in medicine or veterinary medicine.
    They can also be used against bacterial infections in sensitivities of these compounds.
    The pharmaceutical compositions are marketed as mixtures, containing (I) in the form of an acid or, when their solubility is not sufficient, in the form of a salt.
    Such pharmaceutical compositions may be solid or liquid and may be, in the form of tablets, pilnhl, granules, ointments, creams, gels or injections.
    Doses can vary widely, in particular, depending on the type and severity of the infection, and also depending on the method of administration. In general, for an adult patient, when administered as an injection, this dose varies from 0.250 to 4 grams per day. For example, it is possible to prepare ampoules for injections containing: CM 40.953, g1
    Water for injection, ml 5
    Enough amount
    sodium carbonate with a pH of -6.5
    权利要求:
    Claims (1)
    [1]
    METHOD FOR PRODUCING CEPHALOSPORIN-1-OXIDE DERIVATIVES of the general formula where R, and R 2 - * methyl or
    R | and R 2 together is 1,3-propylene;
    Ry - 1H-1,2,4-triazol-3-yl,
    5-amino-1H-1,2,4-triazol-3-yl, 2-amino-1,3,4-thiadiazol-5-ip, 2-Ch <ercapto- '
    1,3,4-thiadiazol-5-yl • or 3-hydroxypyridyl-2,. in the form of syn-isomers and <; n »o-C-Coo-d-CHy
    R t CH 3 where R f have the indicated meanings; a protecting group of an amino group such as trityl, as a syn-isomer, in an inert organic solvent such as methylene chloride, in the presence of carbodiimide and an organic base at room temperature, the resulting product is reacted with a heterocyclic thiol of the formula
    R SH, where Ry has the indicated meanings, in an inert organic solvent such as dimethylformamide, in the presence of an inorganic or organic base at room temperature, followed by removal of the amino and carboxy protecting groups by acid hydrolysis and isolation of the desired product.
    1 1114338
    类似技术:
    公开号 | 公开日 | 专利标题
    CH641467A5|1984-02-29| -CARBAMOYLOXIMINOACETAMIDO) -CEPHALOSPORINE.
    SU1114338A3|1984-09-15|Process for preparing derivatives of cephalosporin-1-oxide
    SU1480763A3|1989-05-15|Method of producing derivatives of 1-surfo-2-oxoazetidinone or their salts or esters
    SU1151213A3|1985-04-15|Method of obtaining cephalosporins or salts thereof
    CA1187496A|1985-05-21|Thiolesters, process for preparing the same and theiruse as intermediate products
    US4463179A|1984-07-31|1H-1,2,3-triazol-5-ylthio ester of N-carbobenzyloxy-p-hydroxyphenylglycine
    EP0044238B1|1984-02-01|Cephalosporin sulfoxides, process for their preparation and pharmaceutical compositions containing them
    EP0000272B1|1982-05-05|7-acylamino-3-substituted-3-cephem-4-carboxylic acids, processes for their preparation and pharmaceutical compositions containing them
    DE2714419C2|1985-12-05|Cephalosporin derivatives, processes for their preparation and pharmaceuticals
    CH654311A5|1986-02-14|1-OXADETHIACEPHALOSPORINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF.
    FR2530248A1|1984-01-20|NOVEL DERIVATIVES OF CEPHALOSPORINS, PROCESS FOR THEIR PREPARATION AND ANTIBIOTIC DRUGS CONTAINING SAID DERIVATIVES
    US4064242A|1977-12-20|7-Acylamino-3-[1-|tetrazole-5-ylthiomethyl]-3-cephem-4-carboxylic acids
    US3953439A|1976-04-27|Substituted phenylglycylcephalosporins
    US4057631A|1977-11-08|7-|-3-|-3-cephem-4-carboxylic acids
    US4005081A|1977-01-25|3-Heterothiomethyl-7α-methoxy-7β-tetrazolylmethylthioacetamido-3-cephem derivatives
    FI68839C|1985-11-11|THERAPEUTIC FORM OF THERAPEUTIC ACID THERAPEUTIC ANVAENDBAR-6- | -ALPH | ACETAMIDO) PENICILLANSYRA
    US4107440A|1978-08-15|Intermediates for preparing substituted phenylglycylcephalosporins
    US4081441A|1978-03-28|Antibacterial agents
    US4238608A|1980-12-09|7-[2-|-2-substituted thio-acetamido] cephalosporins
    DE2356704A1|1974-05-22|3- | CEPHALOSPORINE COMPOUNDS AND THEIR PHARMACOLOGICALLY COMPATIBLE SALTS, PROCESS FOR THEIR PRODUCTION AND MEDICINAL PREPARATIONS CONTAINING THESE COMPOUNDS
    GB1604740A|1981-12-16|7-isothiazolylthioacetamido-7-methoxycephalosporanic acid derivatives
    US4013765A|1977-03-22|Compositions and methods for treating bacterial infections with substituted acetamidocephalosporins
    US4044047A|1977-08-23|Intermediates for preparing substituted phenylglycylcephalosporins
    US4013764A|1977-03-22|Pharmaceutical compositions comprising substituted phenylglycylcephalosporins and methods of treating bacterial infections
    CH627757A5|1982-01-29|Process for the preparation of cephalosporin derivatives and their salts
    同族专利:
    公开号 | 公开日
    PH18949A|1985-11-14|
    FI73221B|1987-05-29|
    EP0080944B1|1985-08-28|
    SG12188G|1989-01-27|
    DD204257A5|1983-11-23|
    ZA828598B|1983-09-28|
    US4609654A|1986-09-02|
    PT75905A|1982-12-01|
    GR76739B|1984-08-30|
    CS232743B2|1985-02-14|
    PT75905B|1985-10-04|
    NO823930L|1983-06-02|
    CS859582A2|1984-02-13|
    PL132054B1|1985-01-31|
    IE822721L|1983-06-01|
    AU564235B2|1987-08-06|
    IL67285D0|1983-03-31|
    NO159857C|1989-02-15|
    ES517840A0|1983-08-16|
    NO159857B|1988-11-07|
    YU265482A|1985-03-20|
    JPS58103392A|1983-06-20|
    HU186999B|1985-10-28|
    HU186998B|1985-10-28|
    FI73221C|1987-09-10|
    ES8308331A1|1983-08-16|
    FI824043A0|1982-11-24|
    AU9094882A|1983-06-09|
    MA19659A1|1983-07-01|
    IL67285A|1985-11-29|
    KR880001775B1|1988-09-15|
    CA1189854A|1985-07-02|
    EG15644A|1986-09-30|
    EP0080944A1|1983-06-08|
    IE54173B1|1989-07-05|
    KR840002406A|1984-07-21|
    FR2517309A1|1983-06-03|
    DE3265901D1|1985-10-03|
    FI824043L|1983-06-02|
    OA07262A|1984-04-30|
    PL239271A1|1983-06-06|
    AT15199T|1985-09-15|
    NZ202658A|1985-07-12|
    DK532282A|1983-06-02|
    FR2517309B1|1985-03-22|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB694060A|1949-12-27|1953-07-15|Bataafsche Petroleum|Process for the manufacture of ethers of glycerols|
    US4165430A|1976-03-19|1979-08-21|Glaxo Laboratories Limited|Cephalosporins having a 7-carboxy substituted α-etherified oximinoarylacetamido) group|
    DE2716677C2|1977-04-15|1985-10-10|Hoechst Ag, 6230 Frankfurt|Cephem derivatives and processes for their preparation|
    FI800889A|1979-03-22|1980-09-23|Glaxo Group Ltd|KEFALOSPORINANTIBIOTIKA|
    US4237128A|1979-04-12|1980-12-02|E. R. Squibb & Sons, Inc.|7-[2--2-[alkoxyimino]acetamido]cephem sulfoxides|DE150507T1|1983-12-29|1987-02-26|Mochida Pharmaceutical Co., Ltd., Tokio/Tokyo, Jp|CEPHALOSPORINE COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS.|
    JPH0516437B2|1983-12-29|1993-03-04|Mochida Pharm Co Ltd|
    US4840945A|1985-04-01|1989-06-20|Mochida Pharmaceutical Co., Ltd.|Cephalosporin derivatives|
    US4812562A|1985-07-25|1989-03-14|Taisho Pharmaceutical Co., Ltd.|Cephalosporin derivatives|
    HU196814B|1985-10-22|1989-01-30|Biogal Gyogyszergyar|Process for producing new cepheme-carboxylic acid derivatives|
    US4880798A|1986-11-25|1989-11-14|Mochida Pharmaceutical Co., Ltd.|Cephalosporin derivatives|
    JPS63132893A|1986-11-25|1988-06-04|Mochida Pharmaceut Co Ltd|Novel cephalosporin derivative, production thereof and antibacterial agent containing said derivative as active ingredient|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    FR8122506A|FR2517309B1|1981-12-01|1981-12-01|
    [返回顶部]